Efficient, specific and targeted delivery of genes to the lung

Therapeutic Delivery

Volumn 1, Issue 1, 2010, Pages 133-148

  Pfeifer, Corinna ^a,b   Himmel, Anne ^a,b   Geiger, Johannes Peter ^a,b   Aneja, Manish K ^a   Rudolph, Carsten ^a,b  

^a UNIVERSITY OF MUNICH   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALPHA 1 ANTITRYPSIN; ANTINEOPLASTIC AGENT; BELAGENPUMATUCEL L; CLENBUTEROL; GENDICINE; ILOPROST; INTERLEUKIN 2; LENTIVIRUS VECTOR; LIPID; LIPOSOME; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; NANOPARTICLE; PARVOVIRUS VECTOR; PLASMID DNA; POLYETHYLENEIMINE; POLYMER; PROTEIN P53; RETROVIRUS VECTOR; TRANSFORMING GROWTH FACTOR BETA2; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN;

ABSENCE OF SIDE EFFECTS; ADVANCED CANCER; ALPHA 1 ANTITRYPSIN DEFICIENCY; ANTISENSE VECTOR; CYSTIC FIBROSIS; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG SPECIFICITY; DRUG TARGETING; DRUG TOLERABILITY; ELECTROPORATION; GENE DELIVERY SYSTEM; GENE EXPRESSION REGULATION; GENE TARGETING; HEAD AND NECK CANCER; HUMAN; IMMUNOGENICITY; LIPOSOMAL GENE DELIVERY SYSTEM; LUNG DISEASE; LUNG NON SMALL CELL CANCER; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; PSEUDOTYPING; REVIEW; SEROTYPE; SINGLE DRUG DOSE; SQUAMOUS CELL CARCINOMA; UNSPECIFIED SIDE EFFECT; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT;

EID: 79954513885     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.10.11     Document Type: Review

References (143)

1. Breeze RG, Wheeldon EB. The cells of the pulmonary airways. Am. Rev. Respir. Dis. 116(4), 705-777 (1977). (Pubitemid 8206010)
2. Sanders N, Rudolph C, Braeckmans K, De Smedt SC, Demeester J. Extracellular barriers in respiratory gene therapy. Adv. Drug Deliv. Rev. 61(2), 115-127 (2008).
3. Davis PB, Cooper MJ. Vectors for airway gene delivery. AAPS J. 9(1), E11-E17 (2007). Viral and nonviral vectors are reviewed with their applications in lung gene therapy.
4. Yang Y, Li Q, Ertl H, Wilson J. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J. Virol. 69, 2004-2015 (1995).
5. Lee TW, Matthews DA, Blair GE. Novel molecular approaches to cystic fibrosis gene therapy. Biochem. J. 387(1), 1-15 (2005). (Pubitemid 40524069)
6. Ogris M, Steinlein P, Kursa M, Mechtler K, Kircheis R, Wagner E. The size of DNA/ transferrin-PEI complexes is an important factor for gene expression in cultured cells. Gene Ther. 5(10), 1425-1433 (1998). (Pubitemid 28482671)
7. Scherer F, Anton M, Schillinger U et al. Magnetofection: enhancing and targeting gene delivery by magnetic force in vitro and in vivo. Gene Ther. 9(2), 102-109 (2002). (Pubitemid 34189525)
8. Gersting SW, Schillinger U, Lausier J et al. Gene delivery to respiratory epithelial cells by magnetofection. J. Gene Med. 6(8), 913-922 (2004). (Pubitemid 40228107)
9. Xenariou S, Griesenbach U, Ferrari S et al. Using magnetic forces to enhance non-viral gene transfer to airway epithelium in vivo. Gene Ther. 13(21), 1545-1552 (2006). (Pubitemid 44567151)
10. Dames P, Gleich B, Flemmer A et al. Targeted delivery of magnetic aerosol droplets to the lung. Nat. Nanotechnol. 2(8), 495-499 (2007). (Pubitemid 47220067)
11. Plank C. Nanomagnetosols: magnetism opens up new perspectives for targeted aerosol delivery to the lung. Trends Biotechnol. 26(2), 59-63 (2008).
12. Dames P, Lesina E, Rudolph C. Aerosol gene delivery to the lungs of mice guided by magnetic forces. Mol. Ther. 15, 2007
13. Gehl J. Electroporation: theory and methods, perspectives for drug delivery, gene therapy and research. Acta Physiol. Scand. 177(4), 437-447 (2003). (Pubitemid 36411581)
14. Dean DA, Machado-Aranda D, Blair- Parks K, Yeldandi AV, Young Jl. Electroporation as a method for high-level nonviral gene transfer to the lung. Gene Ther. 10(18), 1608-1615 (2003). (Pubitemid 37063267)
15. Suzuki R, Namai E, Oda Y et al. Cancer gene therapy by IL-12 gene delivery using liposomal bubbles and tumoral ultrasound exposure. J. Control. Release 142(2), 245-250 (2009).
16. Xenariou S, Griesenbach U, Liang HD et al. Use of ultrasound to enhance nonviral lung gene transfer in vivo. Gene Ther. 14(9), 768-774 (2007). (Pubitemid 46585658)
17. Gautam A, Densmore CL, Golunski E, Xu B, Waldrep JC. Transgene expression in mouse airway epithelium by aerosol gene therapy with PEI-DNA complexes. Mol. Ther. 3(4), 551-556 (2001). (Pubitemid 32509849)
18. Bragonzi A, Conese M. Non-viral approach toward gene therapy of cystic fibrosis lung disease. Curr. Gene Ther. 2(3), 295-305 (2002).
19. Rudolph C, Lausier J, Naundorf S, Muller RH, Rosenecker J. In vivo gene delivery to the lung using polyethylenimine and fractured polyamidoamine dendrimers. J. Gene Med. 2(4), 269-278 (2000).
20. Brown BD, Sitia G, Annoni A et al. In vivo administration of lentiviral vectors triggers a type I interferon response that restricts hepatocyte gene transfer and promotes vector clearance. Blood 109(7), 2797-2805 (2007). (Pubitemid 46482074)
21. Lee TWR, Matthews DA, Blair GE. Novel molecular approaches to cystic fibrosis gene therapy. Biochem. J. 387, 1-15 (2005). (Pubitemid 40524069)
22. Guillaume-Gable C, Floch V, Mercier B et al. Cationic phosphonolipids as nonviral gene transfer agents in the lungs of mice. Hum. Gene Ther. 9(16), 2309-2319 (1998). (Pubitemid 28523980)
23. Barron LG, Gagne L, Szoka FC Jr. Lipoplex-mediated gene delivery to the lung occurs within 60 minutes of intravenous administration. Hum. Gene Ther. 10(10), 1683-1694 (1999). (Pubitemid 29328212)
24. Ruiz FE, Clancy JP, Perricone MA et al. A clinical inflammatory syndrome attributable to aerosolized lipid-DNA administration in cystic fibrosis. Hum. Gene Ther. 12(7), 751-761 (2001). (Pubitemid 32692341)
25. Parker AL, Newman C, Briggs S, Seymour L, Sheridan PJ. Nonviral gene delivery: techniques and implications for molecular medicine. Expert Rev. Mol. Med. 5(22), 1-15 (2003).
26. Marshall J, Nietupski JB, Lee ER et al. Cationic lipid structure and formulation considerations for optimal gene transfection of the lung. J. Drug Target. 7(6), 453-469 (2000). (Pubitemid 30184581)
27. Felgner PL, Gadek TR, Holm M et al. Lipofection: a highly efficient, lipidmediated DNA-transfection procedure. Proc. Natl Acad. Sci. USA 84(21), 7413-7417 (1987).
28. Li S, Huang L. In vivo gene transfer via intravenous administration of cationic lipid-protamine-DNA (LPD) complexes. Gene Ther. 4(9), 891-900 (1997). (Pubitemid 27437714)
29. Kuruba R, Wilson A, Gao X, Li S. Targeted delivery of nucleic-acid-based therapeutics to the pulmonary circulation. AAPS J. 11(1), 23-30 (2009).
30. Oudrhiri N, Vigneron JP, Peuchmaur M, Leclerc T, Lehn JM, Lehn P. Gene transfer by guanidinium-cholesterol cationic lipids into airway epithelial cells in vitro and in vivo. Proc. Natl Acad. Sci. USA 94(5), 1651-1656 (1997). (Pubitemid 27113890)
31. Fortunati E, Bout A, Zanta MA, Valerio D, Scarpa M. In vitro and in vivo gene transfer to pulmonary cells mediated by cationic liposomes. Biochim. Biophys. Acta 1306(1), 55-62 (1996). (Pubitemid 26120714)
32. Noone PG, Hohneker KW, Zhou Z et al. Safety and biological efficacy of a lipid- CFTR complex for gene transfer in the nasal epithelium of adult patients with cystic fibrosis. Mol. Ther. 1(1), 105-114 (2000).
33. Hemmi H, Takeuchi O, Kawai T et al. A Toll-like receptor recognizes bacterial DNA. Nature 408(6813), 740-745 (2000). (Pubitemid 32015992)
34. Hyde SC, Pringle IA, Abdullah S et al. CPG-free plasmids confer reduced inflammation and sustained pulmonary gene expression. Nat. Biotechnol. 26(5), 549-551 (2008). (Pubitemid 351668040)
35. Urtti A, Polansky J, Lui GM, Szoka FC. Gene delivery and expression in human retinal pigment epithelial cells: effects of synthetic carriers, serum, extracellular matrix and viral promoters. J. Drug Target. 7(6), 413-421 (2000). (Pubitemid 30184578)
36. Zelphati O, Nguyen C, Ferrari M, Felgner J, Tsai Y, Felgner Pl. Stable and monodisperse lipoplex formulations for gene delivery. Gene Ther. 5(9), 1272-1282 (1998). (Pubitemid 28448437)
37. Stavridis JC, Deliconstantinos G, Psallidopoulos MC, Armenakas NA, Hadjiminas DJ, Hadjiminas J. Construction of transferrin-coated liposomes for in vivo transport of exogenous DNA to bone marrow erythroblasts in rabbits. Exp. Cell Res. 164(2), 568-572 (1986). (Pubitemid 16042103)
38. Dzau VJ, Mann MJ, Morishita R, Kaneda Y. Fusigenic viral liposome for gene therapy in cardiovascular diseases. Proc. Natl Acad. Sci. USA 93(21), 11421-11425 (1996). (Pubitemid 26347136)
39. Willis M, Forssen E. Ligand-targeted liposomes. Adv. Drug Deliv. Rev. 29(3), 249-271 (1998). (Pubitemid 28090045)
40. Cryan SA. Carrier-based strategies for targeting protein and peptide drugs to the lungs. AAPS J. 7(1), E20-E41 (2005).
41. Bruck A, Abu-Dahab R, Borchard G, Schafer UF, Lehr CM. Lectinfunctionalized liposomes for pulmonary drug delivery: interaction with human alveolar epithelial cells. J. Drug Target. 9(4), 241-251 (2001). (Pubitemid 32776360)
42. Abu-Dahab R, Schafer UF, Lehr CM. Lectin-functionalized liposomes for pulmonary drug delivery: effect of nebulization on stability and bioadhesion. Eur. J. Pharm. Sci. 14(1), 37-46 (2001). (Pubitemid 32655413)
43. Boussif O, Lezoualc'h F, Zanta MA et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc. Natl Acad. Sci. USA 92(16), 7297-7301 (1995).
44. Dunlap DD, Maggi A, Soria MR, Monaco L. Nanoscopic structure of DNA condensed for gene delivery. Nucleic Acids Res. 25(15), 3095-3101 (1997). (Pubitemid 27331404)
45. Kircheis R, Kichler A, Wallner G et al. Coupling of cell-binding ligands to polyethylenimine for targeted gene delivery. Gene Ther. 4(5), 409-418 (1997). (Pubitemid 27226583)
46. Chul Cho K, Hoon Jeong J, Jung Chung H, Joe Co, Wan Kim S, Gwan Park T. Folate receptor-mediated intracellular delivery of recombinant caspase-3 for inducing apoptosis. J. Control. Release 108(1), 121-131 (2005).
47. Elfinger M, Maucksch C, Rudolph C. Characterization of lactoferrin as a targeting ligand for nonviral gene delivery to airway epithelial cells. Biomaterials 28(23), 3448-3455 (2007). (Pubitemid 46726633)
48. Blessing T, Kursa M, Holzhauser R, Kircheis R, Wagner E. Different strategies for formation of pegylated EGF-conjugated PEI/DNA complexes for targeted gene delivery. Bioconjug. Chem. 12(4), 529-537 (2001). (Pubitemid 32696226)
49. Weiss SI, Sieverling N, Niclasen M et al. Uronic acids functionalized polyethyleneimine (PEI)-polyethyleneglycol (PEG)-graft-copolymers as novel synthetic gene carriers. Biomaterials 27(10), 2302-2312 (2006). (Pubitemid 41774541)
50. Geiger J, Aneja MK, Hasenpusch G et al. Targeting of the prostacyclin specific IP(1) receptor in lungs with molecular conjugates comprising prostaglandin I(2) analogues. Biomaterials 31(10), 2903-2911 (2009).
51. Elfinger M, Pfeifer C, Uezguen S et al. Self-assembly of ternary insulin- polyethylenimine (PEI)-DNA nanoparticles for enhanced gene delivery and expression in alveolar epithelial cells. Biomacromolecules 10(10), 2912-2920 (2009).
52. Elfinger M, Geiger J, Hasenpusch G et al. Targeting of the b2-adrenoceptor increases nonviral gene delivery to pulmonary epithelial cells in vitro and lungs in vivo. J. Control. Release 135(3), 234-241 (2009).
53. Botos I, Liu L, Wang Y, Segal DM, Davies DR. The Toll-like receptor 3:dsRNA signaling complex. Biochim. Biophys. Acta 1789(9-10), 667-674 (2009).
54. Bout A, Perricaudet M, Baskin G et al. Lung gene therapy: in vivo adenovirus-mediated gene transfer to rhesus monkey airway epithelium. Hum. Gene Ther. 5, 3-10 (1994). (Pubitemid 24310529)
55. Pickles RJ, McCarty D, Matsui H. Limited entry of adenovirus vectors into welldifferentiated airway epithelium is responsible for inefficient gene transfer. J. Virol. 72(7), 6014-6023 (1998). (Pubitemid 28283390)
56. Pickles RJ, Fahrner JA, Jennielizabeth MP, Boucher RC, Bergelson JM. Retargeting the coxsackievirus and adenovirus receptor to the apical surface of polarized epithelial cells reveals the glycocalyx as a barrier to adenovirus-mediated gene transfer. J. Virol. 74(13), 6050-6057 (2000). (Pubitemid 30412976)
57. Gregory LG, Harbottle RP, Lawrence L, Krapton HJ, Themis M, Coutelle C. Enhancement of adenovirus-mediated gene transfer to the airways by DEAE dextran and sodium caprate in vivo. Mol. Ther. 7(1), 19-26 (2003). (Pubitemid 36305355)
58. Lee J, Zabner J, Welsh M. Delivery of an adenovirus vector in a calcium phosphate coprecipitate enhances the therapeutic index of gene T transfer to airway epithelia. Hum. Gene Ther. 10(4), 603-613 (1999). (Pubitemid 29131326)
59. Wang G, Zabner J, Deering C et al. Increasing epithelial junction permeability enhances gene transfer to airway epithelia in vivo. Am. J. Respir. Cell Mol. Biol. 22(2), 129-138 (2000). (Pubitemid 30351473)
60. Chu Q, George JS, Lukason M. EGTA enhancement of adenovirus-mediated gene transfer to mouse tracheal epithelium in vivo. Hum. Gene Ther. 12(5), 455-467 (2001). (Pubitemid 32511069)
61. Kaplan J, Pennington S, George JS. Potentiation of gene transfer to the mouse lung by complexes of adenovirus vector and polycations improves therapeutic potential. Hum. Gene Ther. 9(10), 1469-1479 (1998). (Pubitemid 28379086)
62. Parsons D, Grubb B, Johnson L, Boucher R. Enhanced in vivo airway gene transfer via transient modification of host barrier properties with a surface-active agent. Hum. Gene Ther. 9(18), 2661-2672 (1998). (Pubitemid 29027009)
63. Koehler D, Frndova H, Leung K et al. Aerosol delivery of an enhanced helperdependent adenovirus formulation to rabbit lung using an intratracheal catheter. J. Gene Med. 7(11), 1409-1420 (2005). (Pubitemid 41672399)
64. O'Neal W, Zhou H, Morral N et al. Toxicological comparison of E2a-deleted and first-generation adenoviral vectors expressing a1-antitrypsin after systemic delivery. Hum. Gene Ther. 20(9), 1587-1598 (1998). (Pubitemid 28382960)
65. Chirmule N, Raper S, Burkly L et al. Readministration of adenovirus vector in nonhuman primate lungs by blockade of CD40-CD40 ligand interactions. J. Virol. 74(7), 3345-3352 (2000). (Pubitemid 30143760)
66. Kolb M, Inman M, Margetts P, Galt T, Gauldie J. Budesonide enhances repeated gene transfer and expression in the lung with adenoviral vectors. Am. J. Respir. Crit. Care Med. 164(5), 866-872 (2001). (Pubitemid 32881926)
67. Mitani K, Graham FL, Caskey CT, Kochanek S. Rescue, propagation, and partial purification of a helper virusdependent adenovirus vector. Proc. Natl Acad. Sci. USA 92(9), 3854-3858 (1995).
68. Toietta G, Koehler DR, Finegold MJ, Lee B, Hu J, Beaudet AL. Reduced inflammation and improved airway expression using helper-dependent adenoviral vectors with a K18 promoter. Mol. Ther. 7(5), 649-658 (2003). (Pubitemid 36626245)
69. Samulski RJ, Zhu X, Xiao X et al. Targeted integration of adeno-associated virus (AAV) into human chromosome 19. EMBO J. 10(12), 3941-3950 (1991). (Pubitemid 21905423)
70. Allocca M, Doria M, Petrillo M et al. Serotype-dependent packaging of large genes in adeno-associated viral vectors results in effective gene delivery in mice. J. Clin. Invest. 118(5), 1955-1964 (2008). (Pubitemid 351632397)
71. Mccarty DM, Young SM Jr, Samulski RJ. Integration of adeno-associated virus (AAV) and recombinant AAV vectors. Ann. Rev. Genet. 38, 819-845 (2004). (Pubitemid 40013747)
72. Tarantal AF, Lee CC. Long-term luciferase expression monitored by bioluminescence imaging after adeno-associated virus-mediated fetal gene delivery in rhesus monkeys (Macaca mulatta). Hum. Gene Ther. 21(2), 143-148 (2010).
73. Moss RB, Milla C, Colombo J et al. Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled Phase IIB trial. Hum. Gene Ther. 18(8), 726-732 (2007). (Pubitemid 47378069)
74. Yan Z, Lei-Butters DC, Liu X et al. Unique biologic properties of recombinant AAV1 transduction in polarized human airway epithelia. J. Biol. Chem. 281(40), 29684-29692 (2006). (Pubitemid 44536977)
75. Virella-Lowell I, Zusman B, Foust K et al. Enhancing rAAV vector expression in the lung. J. Gene Med. 7(7), 842-850 (2005). (Pubitemid 41015532)
76. Zabner J, Seiler M, Walters R et al. Adenoassociated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer. J. Virol. 74(8), 3852-3858 (2000). (Pubitemid 30180327)
77. Halbert CL, Allen JM, Miller AD. Adenoassociated virus type 6 (AAV6) vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared with that of AAV2 vectors. J. Virol. 75(14), 6615-6624 (2001). (Pubitemid 32578181)
78. Limberis MP, Wilson JM. Adeno-associated virus serotype 9 vectors transduce murine alveolar and nasal epithelia and can be readministered. Proc. Natl Acad. Sci. USA 103(35), 12993-12998 (2006). (Pubitemid 44338905)
79. Li W, Zhang L, Johnson JS et al. Generation of novel AAV variants by directed evolution for improved CFTR delivery to human ciliated airway epithelium. Mol. Ther. 17(12), 2067-2077 (2009).
80. Halbert CL, Lam SL, Miller AD. Highefficiency promoter-dependent transduction by adeno-associated virus type 6 vectors in mouse lung. Hum. Gene Ther. 18(4), 344-354 (2007). (Pubitemid 46709346)
81. Halbert CL, Standaert TA, Aitken ML, Alexander IE, Russell DW, Miller AD. Transduction by adeno-associated virus vectors in the rabbit airway: efficiency, persistence, and readministration. J. Virol. 71(8), 5932-5941 (1997). (Pubitemid 27304930)
82. Halbert CL, Standaert TA, Wilson CB, Miller AD. Successful readministration of adeno-associated virus vectors to the mouse lung requires transient immunosuppression during the initial exposure. J. Virol. 72(12), 9795-9805 (1998). (Pubitemid 28520845)
83. Murphy SL, Li H, Mingozzi F et al. Diverse IgG subclass responses to adeno-associated virus infection and vector administration. J. Med. Virol. 81(1), 65-74 (2009).
84. Boutin S, Monteilhet V, Veron P et al. Prevalence of serum IgG and neutralizing factors against adeno-associated virus types 1, 2, 5, 6, 8 and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum. Gene Ther. 21(6), 704-712 (2010).
85. Halbert CL, Miller AD, McNamara S et al. Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and in cystic fibrosis and normal populations: implications for gene therapy using AAV vectors. Hum. Gene Ther. 17(4), 440-447 (2006).
86. McTaggart S, Al-Rubeai M. Retroviral vectors for human gene delivery. Biotechnol. Adv. 20(1), 1-31 (2002). (Pubitemid 34458446)
87. Engelhardt JF, Yankaskas JR, Wilson JM. In vivo retroviral gene transfer into human bronchial epithelia of xenografts. J. Clin. Invest. 90(6), 2598-2607 (1992). (Pubitemid 23010083)
88. Hacein-Bey-Abina S, Von Kalle C, Schmidt M et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 348(3), 255-256 (2003). (Pubitemid 36077924)
89. Loew R, Meyer Y, Kuehlcke K et al. A new PG13-based packaging cell line for stable production of clinical-grade self-inactivating g-retroviral vectors using targeted integration. Gene Ther. 17(2), 272-280 (2009).
90. Cattoglio C, Facchini G, Sartori D et al. Hot spots of retroviral integration in human CD34+ hematopoietic cells. Blood 110(6), 1770-1778 (2007). (Pubitemid 47443887)
91. Aiken C. Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic pathway and suppresses both the requirement for Nef and the sensitivity to cyclosporin A. J. Virol. 71(8), 5871-5877 (1997). (Pubitemid 27304923)
92. Goldman MJ, Lee PS, Yang JS, Wilson JM. Lentiviral vectors for gene therapy of cystic fibrosis. Hum. Gene Ther. 8(18), 2261-2268 (1997). (Pubitemid 128752227)
93. Buckley SM, Howe SJ, Sheard V et al. Lentiviral transduction of the murine lung provides efficient pseudotype and developmental stage-dependent cell-specific transgene expression. Gene Ther. 15(16), 1167-1175 (2008).
94. Wang G, Slepushkin V, Zabner J et al. Feline immunodeficiency virus vectors persistently transduce nondividing airway epithelia and correct the cystic fibrosis defect. J. Clin. Invest. 104(11), R55-R62 (1999). (Pubitemid 30002376)
95. Chen X, Hyatt BA, Mucenski ML, Mason RJ, Shannon JM. Identification and characterization of a lysophosphatidylcholine acyltransferase in alveolar type II cells. Proc. Natl Acad. Sci. USA 103(31), 11724-11729 (2006). (Pubitemid 44182518)
96. Kremer KL, Dunning KR, Parsons DW, Anson DS. Gene delivery to airway epithelial cells in vivo: a direct comparison of apical and basolateral transduction strategies using pseudotyped lentivirus vectors. J. Gene Med. 9(5), 362-368 (2007). (Pubitemid 46796582)
97. Limberis M, Anson DS, Fuller M, Parsons DW. Recovery of airway cystic fibrosis transmembrane conductance regulator function in mice with cystic fibrosis after single-dose lentivirus-mediated gene transfer. Hum. Gene Ther. 13(16), 1961-1970 (2002). (Pubitemid 35341037)
98. Stocker AG, Kremer KL, Koldej R, Miller DS, Anson DS, Parsons DW. Single-dose lentiviral gene transfer for lifetime airway gene expression. J. Gene Med. 11(10), 861-867 (2009).
99. Kobinger GP, Weiner DJ, Yu QC, Wilson JM. Filovirus-pseudotyped lentiviral vector can efficiently and stably transduce airway epithelia in vivo. Nat. Biotechnol. 19(3), 225-230 (2001). (Pubitemid 32220562)
100. Medina MF, Kobinger GP, Rux J et al. Lentiviral vectors pseudotyped with minimal filovirus envelopes increased gene transfer in murine lung. Mol. Ther. 8(5), 777-789 (2003). (Pubitemid 37527453)
101. Kobinger GP, Limberis MP, Somanathan S, Schumer G, Bell P, Wilson JM. Human immunodeficiency viral vector pseudotyped with the spike envelope of severe acute respiratory syndrome coronavirus transduces human airway epithelial cells and dendritic cells. Hum. Gene Ther. 18(5), 413-422 (2007). (Pubitemid 46850133)
102. Morizono K, Xie Y, Ringpis GE et al. Lentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection. Nat. Med. 11(3), 346-352 (2005). (Pubitemid 40460565)
103. Sinn PL, Arias AC, Brogden KA, McCray PB Jr. Lentivirus vector can be readministered to nasal epithelia without blocking immune responses. J. Virol. 82(21), 10684-10692 (2008). (Pubitemid 352691165)
104. Griesenbach U, Alton EW. Gene transfer to the lung: lessons learned from more than 2 decades of CF gene therapy. Adv. Drug Deliv. Rev. 61(2), 128-139 (2009).
105. Stern M, Caplen NJ, Browning JE et al. The effect of mucolytic agents on gene transfer across a CF sputum barrier in vitro. Gene Ther. 5(1), 91-98 (1998). (Pubitemid 28045074)
106. Virella-Lowell I, Poirier A, Chesnut KA, Brantly M, Flotte TR. Inhibition of recombinant adeno-associated virus (rAAV) transduction by bronchial secretions from cystic fibrosis patients. Gene Ther. 7(20), 1783-1789 (2000).
107. Perricone MA, Rees DD, Sacks CR, Smith KA, Kaplan JM, St George JA. Inhibitory effect of cystic fibrosis sputum on adenovirus-mediated gene transfer in cultured epithelial cells. Hum. Gene Ther. 11(14), 1997-2008 (2000).
108. McLean C, Greene CM, McElvaney NG. Gene targeted therapeutics for liver disease in a-1 antitrypsin deficiency. Biologics 3, 63-75 (2009).
109. Brigham KL, Lane KB, Meyrick B et al. Transfection of nasal mucosa with a normal a1-antitrypsin gene in a1-antitrypsin-deficient subjects: comparison with protein therapy. Hum. Gene Ther. 11(7), 1023-1032 (2000). (Pubitemid 30250119)
110. Brantly ML, Spencer LT, Humphries M et al. Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 al-antitrypsin (AAT) vector in AAT-deficient adults. Hum. Gene Ther. 17(12), 1177-1186 (2006). (Pubitemid 44975135)
111. Brantly ML, Chulay JD, Wang L et al. Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Proc. Natl Acad. Sci. USA 106(38), 16363-16368 (2009).
112. Junker K, Wiethege T, Muller KM, Thomas M. p53 tumour-suppressor gene in non-small-cell lung cancer with neoadjuvant therapy. J. Cancer Res. Clin. Oncol. 126(4), 238-245 (2000). (Pubitemid 30183028)
113. Swisher SG, Roth JA, Komaki R et al. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin. Cancer Res. 9(1), 93-101 (2003). (Pubitemid 36109720)
114. Schuler M, Rochlitz C, Horowitz JA et al. A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small-cell lung cancer. Hum. Gene Ther. 9(14), 2075-2082 (1998). (Pubitemid 28463925)
115. Schuler M, Herrmann R, De Greve JL et al. Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter Phase II study. J. Clin. Oncol. 19(6), 1750-1758 (2001). (Pubitemid 32230877)
116. Peng Z. Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum. Gene Ther. 16(9), 1016-1027 (2005). (Pubitemid 41324561)
117. Roth JA, Nguyen D, Lawrence DD et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat. Med. 2(9), 985-991 (1996). (Pubitemid 26306836)
118. Nemunaitis J, Sterman D, Jablons D et al. Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J. Natl Cancer Inst. 96(4), 326-331 (2004). (Pubitemid 38256277)
119. Ramlau R, Quoix E, Rolski J et al. A Phase II study of Tg4010 (Mva-Muc1-II2) in association with chemotherapy in patients with stage III/IV non-small-cell lung cancer. J. Thorac. Oncol. 3(7), 735-744 (2008).
120. Nemunaitis J, Nemunaitis M, Senzer N et al. Phase II trial of belagenpumatucel-L, a TGF-b2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients. Cancer Gene Ther. 16(8), 620-624 (2009).
121. Zabner J, Couture LA, Gregory RJ, Graham SM, Smith AE, Welsh MJ. Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis. Cell 75(2), 207-216 (1993). (Pubitemid 23320285)
122. Crystal RG, McElvaney NG, Rosenfeld MA et al. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat. Genet. 8(1), 42-51 (1994).
123. Hay JG, McElvaney NG, Herena J, Crystal RG. Modification of nasal epithelial potential differences of individuals with cystic fibrosis consequent to local administration of a normal CFTR cDNA adenovirus gene transfer vector. Hum. Gene Ther. 6(11), 1487-1496 (1995).
124. Knowles MR, Hohneker KW, Zhou Z et al. A controlled study of adenoviral-vectormediated gene transfer in the nasal epithelium of patients with cystic fibrosis. N. Engl. J. Med. 333(13), 823-831 (1995).
125. Zabner J, Ramsey BW, Meeker DP et al. Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator to the nasal epithelium of patients with cystic fibrosis. J. Clin. Invest. 97(6), 1504-1511 (1996). (Pubitemid 26097041)
126. Bellon G, Michel-Calemard L, Thouvenot D et al. Aerosol administration of a recombinant adenovirus expressing CFTR to cystic fibrosis patients: a Phase I clinical trial. Hum. Gene Ther. 8(1), 15-25 (1997). (Pubitemid 27075339)
127. Harvey BG, Leopold PL, Hackett NR et al. Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus. J. Clin. Invest. 104(9), 1245-1255 (1999). (Pubitemid 29536295)
128. Zuckerman JB, Robinson CB, McCoy KS et al. A Phase I study of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator gene to a lung segment of individuals with cystic fibrosis. Hum. Gene Ther. 10(18), 2973-2985 (1999).
129. Joseph PM, O'Sullivan BP, Lapey A et al. Aerosol and lobar administration of a recombinant adenovirus to individuals with cystic fibrosis. I. Methods, safety, and clinical implications. Hum. Gene Ther. 12(11), 1369-1382 (2001). (Pubitemid 32881343)
130. Perricone MA, Morris JE, Pavelka K et al. Aerosol and lobar administration of a recombinant adenovirus to individuals with cystic fibrosis. II. Transfection efficiency in airway epithelium. Hum. Gene Ther. 12(11), 1383-1394 (2001). (Pubitemid 32881344)
131. Wagner JA, Messner AH, Moran ML et al. Safety and biological efficacy of an adenoassociated virus vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus. Laryngoscope 109(2 Pt 1), 266-274 (1999). (Pubitemid 29075570)
132. Aitken ML, Moss RB, Waltz DA et al. A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease. Hum. Gene Ther. 12(15), 1907-1916 (2001) (Pubitemid 32947233)
133. Wagner JA, Nepomuceno IB, Messner AH et al. A Phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies. Hum. Gene Ther. 13(11), 1349-1359 (2002). (Pubitemid 35034514)
134. Flotte TR, Zeitlin PL, Reynolds TC et al. Phase I trial of intranasal and endobronchial administration of a recombinant adenoassociated virus serotype 2 (rAAV2)-CFTR vector in adult cystic fibrosis patients: a two-part clinical study. Hum. Gene Ther. 14(11), 1079-1088 (2003). (Pubitemid 36851399)
135. Moss RB, Rodman D, Spencer LT et al. Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial. Chest 125(2), 509-521 (2004). (Pubitemid 38223630)
136. Caplen NJ, Alton EW, Middleton PG et al. Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Nat. Med. 1(1), 39-46 (1995).
137. Gill DR, Southern KW, Mofford KA et al. A placebo-controlled study of liposomemediated gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther. 4(3), 199-209 (1997). (Pubitemid 27182073)
138. Porteous DJ, Dorin JR, McLachlan G et al. Evidence for safety and efficacy of DOTAP cationic liposome mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther. 4(3), 210-218 (1997). (Pubitemid 27182074)
139. Zabner J, Cheng SH, Meeker D et al. Comparison of DNA-lipid complexes and DNA alone for gene transfer to cystic fibrosis airway epithelia in vivo. J. Clin. Invest. 100(6), 1529-1537 (1997). (Pubitemid 27425780)
140. Alton EW, Stern M, Farley R et al. Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial. Lancet 353(9157), 947-954 (1999). (Pubitemid 29132602)
141. Hyde SC, Southern KW, Gileadi U et al. Repeat administration of DNA/liposomes to the nasal epithelium of patients with cystic fibrosis. Gene Ther. 7(13), 1156-1165 (2000). (Pubitemid 30458808)
142. Konstan MW, Davis PB, Wagener JS et al. Compacted DNA nanoparticles administered to the nasal mucosa of cystic fibrosis subjects are safe and demonstrate partial to complete cystic fibrosis transmembrane regulator reconstitution. Hum. Gene Ther. 15(12), 1255-1269 (2004). (Pubitemid 40052437)
143. The Journal of Gene Medicine Clinical Trial site www.wiley.co.uk/ genetherapy/clinical